Tokuda Eiichi, Furukawa Yoshiaki
Laboratory for Mechanistic Chemistry of Biomolecules, Department of Chemistry, Keio University, Yokohama 223-8522, Japan.
Int J Mol Sci. 2016 Apr 28;17(5):636. doi: 10.3390/ijms17050636.
Amyotrophic lateral sclerosis (ALS) is a lethal neurodegenerative disease affecting both upper and lower motor neurons, and currently, there is no cure or effective treatment. Mutations in a gene encoding a ubiquitous antioxidant enzyme, Cu,Zn-superoxide dismutase (SOD1), have been first identified as a cause of familial forms of ALS. It is widely accepted that mutant SOD1 proteins cause the disease through a gain in toxicity but not through a loss of its physiological function. SOD1 is a major copper-binding protein and regulates copper homeostasis in the cell; therefore, a toxicity of mutant SOD1 could arise from the disruption of copper homeostasis. In this review, we will briefly review recent studies implying roles of copper homeostasis in the pathogenesis of SOD1-ALS and highlight the therapeutic interventions focusing on pharmacological as well as genetic regulations of copper homeostasis to modify the pathological process in SOD1-ALS.
肌萎缩侧索硬化症(ALS)是一种致命的神经退行性疾病,会影响上下运动神经元,目前尚无治愈方法或有效治疗手段。编码一种普遍存在的抗氧化酶——铜锌超氧化物歧化酶(SOD1)的基因突变,最初被确定为家族性ALS的病因。人们普遍认为,突变的SOD1蛋白通过毒性增加而非生理功能丧失导致疾病。SOD1是一种主要的铜结合蛋白,调节细胞内的铜稳态;因此,突变SOD1的毒性可能源于铜稳态的破坏。在这篇综述中,我们将简要回顾最近暗示铜稳态在SOD1-ALS发病机制中作用的研究,并重点介绍针对铜稳态的药理学和基因调控以改变SOD1-ALS病理过程的治疗干预措施。